Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints
Portfolio Pulse from
Neumora Therapeutics' shares fell by over 83% after its Phase 3 trial for the depression drug navacaprant failed to meet primary endpoints, raising concerns about the drug's efficacy.
January 02, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neumora Therapeutics' stock dropped significantly after its Phase 3 trial for navacaprant, a drug for major depressive disorder, failed to show significant benefits.
The failure of the Phase 3 trial for navacaprant is a major setback for Neumora Therapeutics, leading to a significant drop in stock price. The trial's inability to meet its primary endpoint raises doubts about the drug's future, impacting investor confidence.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100